IN2013MU03121A - - Google Patents

Download PDF

Info

Publication number
IN2013MU03121A
IN2013MU03121A IN3121MU2013A IN2013MU03121A IN 2013MU03121 A IN2013MU03121 A IN 2013MU03121A IN 3121MU2013 A IN3121MU2013 A IN 3121MU2013A IN 2013MU03121 A IN2013MU03121 A IN 2013MU03121A
Authority
IN
India
Prior art keywords
relates
amorphous vortioxetine
amorphous
vortioxetine
salts
Prior art date
Application number
Other languages
English (en)
Inventor
Shri Prakash Dhar Dwivedi
Brij Khera
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Priority to PCT/IN2014/000633 priority Critical patent/WO2015044963A1/en
Priority to US14/916,075 priority patent/US10414741B2/en
Priority to IN3121MU2013 priority patent/IN2013MU03121A/en
Publication of IN2013MU03121A publication Critical patent/IN2013MU03121A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Addiction (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IN3121MU2013 2013-09-30 2014-09-30 IN2013MU03121A (pl)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PCT/IN2014/000633 WO2015044963A1 (en) 2013-09-30 2014-09-30 An amorphous vortioxetine and salts thereof
US14/916,075 US10414741B2 (en) 2013-09-30 2014-09-30 Amorphous vortioxetine and salts thereof
IN3121MU2013 IN2013MU03121A (pl) 2013-09-30 2014-09-30

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN3121MU2013 IN2013MU03121A (pl) 2013-09-30 2014-09-30

Publications (1)

Publication Number Publication Date
IN2013MU03121A true IN2013MU03121A (pl) 2015-07-17

Family

ID=52117938

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3121MU2013 IN2013MU03121A (pl) 2013-09-30 2014-09-30

Country Status (3)

Country Link
US (1) US10414741B2 (pl)
IN (1) IN2013MU03121A (pl)
WO (1) WO2015044963A1 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ201531A3 (cs) * 2015-01-21 2016-08-03 Zentiva, K.S. Polymerem stabilizované amorfní formy vortioxetinu
WO2016125190A2 (en) 2015-02-04 2016-08-11 Mylan Laboratories Limited Novel crystalline forms of vortioxetine, premixes, and processes for the preparation thereof
WO2017041680A1 (zh) * 2015-09-07 2017-03-16 常州方楠医药技术有限公司 一种沃替西汀或其盐的药用组合物及其制备方法
CN106491604A (zh) * 2015-09-07 2017-03-15 常州方楠医药技术有限公司 一种无定型沃替西汀或其盐与药用辅料的组合物及其制备方法
CZ2015633A3 (cs) * 2015-09-16 2017-03-29 Zentiva, K.S. Amorfní forma vortioxetin hydrobromidu stabilizovaná cyklodextrinem
CN106556663B (zh) * 2015-09-30 2018-05-29 成都弘达药业有限公司 一种1-[2-(2,4-二甲基苯基硫烷基)苯基]哌嗪或其盐的检测方法
US20190194154A1 (en) * 2016-01-20 2019-06-27 Amneal Pharmaceuticals Company Gmbh Polymorphic Forms Of Vortioxetine Hydrobromide Tert-Butanolate
WO2018042168A1 (en) * 2016-08-29 2018-03-08 King, Lawrence Stable pharmaceutical composition of vortioxetine hydrobromide
CN106518807A (zh) * 2016-09-17 2017-03-22 北京万全德众医药生物技术有限公司 乳酸沃替西汀晶型的制备方法
US10519121B2 (en) 2016-12-30 2019-12-31 Apicore Us Llc Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts
EP3582759A4 (en) * 2017-02-17 2021-01-06 Unichem Laboratories Ltd BIOEQUIVALENT PHARMACEUTICAL COMPOSITION OF PRE-ORDIOXETINE HYDROBROMIDE
CA3146024A1 (en) * 2019-09-04 2021-03-11 Seasons Biotechnology (Taizhou) Co., Ltd. Coated granule, solid dispersion, and preparation containing vortioxetine hydrobromide for oral taste masking
TR202001040A2 (tr) * 2020-01-23 2021-07-26 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Vorti̇okseti̇n hi̇drobromi̇di̇n kri̇stali̇n c formu
CN112830906B (zh) * 2020-12-31 2022-05-13 微研优仿医药科技(江苏)有限公司 一种伏硫西汀氢溴酸盐α晶型的制备方法
CN113143886A (zh) * 2021-05-07 2021-07-23 苏州康恒研新药物技术有限公司 一种氢溴酸伏硫西汀微丸缓释制剂的制备方法
CN115160258B (zh) * 2022-06-24 2023-11-17 辰欣药业股份有限公司 一种氢溴酸沃替西汀γ晶型的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US119521A (en) * 1871-10-03 Improvement in machines for rolling tapering forms
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
WO2007144005A1 (en) * 2006-06-16 2007-12-21 H. Lundbeck A/S 1- [2- (2, 4-dimethylphenylsulfanyl) -phenyl] piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment
TW201033181A (en) * 2009-02-17 2010-09-16 Lundbeck & Co As H Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine
SG11201403835UA (en) 2012-01-03 2014-10-30 Lundbeck & Co As H Process for the manufacture of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine
US9499504B2 (en) * 2012-09-19 2016-11-22 Sandoz Ag Crystalline form of vortioxetine hydrobromide
WO2014177491A1 (en) * 2013-04-29 2014-11-06 Lek Pharmaceuticals D.D. New solid form of 1-(2-((2,4-dimethylphenyl)thio)phenyl)piperazine hydrobromide
EP3209297A1 (en) * 2014-10-24 2017-08-30 Hexal Aktiengesellschaft Amorphous vortioxetine hydrobromide

Also Published As

Publication number Publication date
US20160214949A1 (en) 2016-07-28
WO2015044963A9 (en) 2015-05-07
WO2015044963A1 (en) 2015-04-02
US10414741B2 (en) 2019-09-17

Similar Documents

Publication Publication Date Title
IN2013MU03121A (pl)
CY1122648T1 (el) Διαδικασια για την παρασκευη συνθεσεων που περιεχουν υαλουρονικο οξυ και υδροχλωρικη μεπιβακαϊνη
PH12016500105A1 (en) Sulfonamides as modulators of sodium channels
NZ710270A (en) Pyridone amides as modulators of sodium channels
PH12016500431A1 (en) Methods and pharmaceutical compositions for the treatment of hepatitis b virus infection
MX368833B (es) Derivados de quinolina y quinazolina amidas como inhibidores de canales de sodio nav1.8 y el uso de los mismos en el tratamiento del dolor.
UA117261C2 (uk) Похідні карбоксаміду та їх застосування як медикаментів для лікування гепатиту b
MX2015016983A (es) Moduladores del transporte nuclear y usos de los mismos.
PH12015502116A1 (en) Biaryl amide compounds as kinase inhibitors
IN2014DN09434A (pl)
PH12016501830A1 (en) Inhibitors of c5a for the treatment of viral pneumonia
MX2015009106A (es) Composiciones de solución sólida y su uso en el tratamiento del dolor intenso.
MX2016005760A (es) Inhibidores de glucogeno sintasa cinasa 3 (gsk-3).
IN2014DN06169A (pl)
UA115357C2 (uk) Похідні піридин-4-ілу
PH12016500465B1 (en) Deoxynojirimycin derivatives and methods of their using
MX360048B (es) Formas cristalinas de acido { [1-ciano-5-(4-clorofenoxi)-4-hidroxi -isoquinolin-3-carbonil]-amino}-acetico.
MX2016008150A (es) Formulaciones de berberina y usos de las mismas.
UA115583C2 (uk) Азетидинілоксифенілпіролідинові сполуки
MX2016005567A (es) Profarmacos de antagonista de (s)-1-fenil-2-(piridin-2-il)etanamin a (nmda).
MX2015007945A (es) Usos y métodos para el tratamiento de enfermedades o afecciones hepáticas.
MX2015015746A (es) Proceso para la preparacion de arformoterol o sal del mismo.
IN2013MU03565A (pl)
PH12015502703A1 (en) Pharmaceutical compositions
IN2013MU03428A (pl)